Earlier this summer, I had a front-row seat for the amazing progress biopharmaceutical companies are making in the battle against cancer. The deluge of data at this year’s American Society for Clinical Oncology (ASCO) meeting provided many reasons to cheer. There were blows struck against some of the biggest cancer killers and impressive progress against
Throughout 2021, lawmakers engaged in a robust debate over ways to lower the cost of prescription drugs. Our industry was at the center of this debate, fighting for reforms that would lower costs at the pharmacy while preserving patient access to life-saving medicines and future innovation. Unfortunately, Congress refused to take a holistic approach that
Over the past several months, many Americans have walked into their local pharmacies weighed down by the constant threat of a deadly coronavirus. By the time they walked out, they got a shot in their arm that will help protect them from COVID-19. For many, getting vaccinated offers more than immunity. It provides relief after
At the start of 2020, our members were focused on continuing their research and development of transformative treatments for the most difficult diseases, such as cell and gene therapies. We planned on making strides on new medicines for chronic diseases like diabetes, heart disease and cancer. And we planned on pushing for policy solutions that
Long after the sun goes down, the work of America’s biopharmaceutical companies continues deep into the night. Researchers and scientists labor around the clock, developing new ways to diagnose, treat and cure COVID-19. While they do, so many of the people they’re working to help stare at the ceiling and wonder how they will afford
Not so long ago, people diagnosed with hepatitis C faced a lifetime of serious complications. The virus would progress slowly, and over time, could cause extensive liver damage. But that’s not the case anymore for the vast majority of patients with the disease. Thanks to medical research and innovation over the past 25 years, patients
Editor’s note: This was part of CDR’s 2019 Pharmacy Outlook in the January 7 issue. Pharmacists are medication experts. Every day, they get to see the remarkable difference innovative treatments can make in their customers’ lives. But like America’s biopharmaceutical companies, they also know those innovative medicines aren’t nearly as meaningful if they are too
Every day at America’s community pharmacies, patients pay a bigger and bigger share of the cost for their prescription medications. But two new studies have revealed one of the puzzling reasons why — and how market-based solutions could help ease the strain on America’s patients. Like any complex U.S. industry, the biopharmaceutical sector relies on
When chain drug store customers are waiting in line at the pharmacy, odds are they have at least one thing on their mind: relief for their disease or condition. The good news is that at the start of 2017, America’s chain drug store customers will see more available treatment options than at any other time
